A Phase 1 interventional study of MK-1167 in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Researchers are looking for new ways to treat Alzheimer's disease (AD). AD is a brain disease that causes a gradual decline in memory, thinking, and ability to carry out daily tasks. MK-1167 is a study medicine designed to treat symptoms of AD. Before giving a study medicine to people with a health condition, researchers first do studies in healthy people to find a safe dose of the study medicine.
The goals of the trial are to learn:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive MK-1167 Form 2 orally.
Drug: MK-1167
Participants receive MK-1167 Form 1 orally.
Drug: MK-1167
Oral administration
Area Under the Curve from Time 0 to Infinity (AUC0-inf) of MK-1167
Blood samples will be collected to determine the AUC0-inf of MK-1167.
Time frame: At designated time points (up to approximately 21 days)
Maximum Plasma Concentration (Cmax) of MK-1167
Blood samples will be collected to determine the Cmax of MK-1167.
Time frame: At designated time points (up to approximately 21 days)
Area Under the Curve from Time 0 to Last Measurable Concentration (AUC0-last) of MK-1167
Blood samples will be collected to determine the AUC0-last of MK-1167.
Time frame: At designated time points (up to approximately 21 days)
Area Under the Curve from Time 0 to 24 hours (AUC0-24) of MK-1167
Blood samples will be collected to determine the AUC0-24 of MK-1167.
Time frame: At designated time points (up to approximately 24 hours)
Concentration at 24 hours (C24) of MK-1167
Blood samples will be collected to determine the C24 of MK-1167.
Time frame: At designated time points (up to approximately 24 hours)
Time to Maximum Serum Concentration (Tmax) of MK-1167
Blood samples will be collected to determine the Tmax of MK-1167.
Time frame: At designated time points (up to approximately 21 days)
Apparent Terminal Half-life (t1/2) of MK-1167
Blood samples will be collected to determine the t1/2 of MK-1167.
Time frame: At designated time points (up to approximately 21 days)
Apparent Clearance after Nonintravenous Administration (CL/F) of MK-1167
Blood samples will be collected to determine the CL/F of MK-1167.
Time frame: At designated time points (up to approximately 21 days)
Apparent Volume of Distribution during Terminal Phase (Vz/F) of MK-1167
Blood samples will be collected to determine the Vz/F of MK-1167.
Time frame: At designated time points (up to approximately 21 days)
Number of Participants Who Experience One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.
Time frame: Up to approximately 78 days
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study treatment due to an AE will be reported.
Time frame: Up to approximately 36 days
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Feb 2026 to primary completion in May 2026, 3 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: MK-1167